Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.47 |
| ▸ | MEN1 | O00255 | 7/20 | 0.47 |
| ▸ | GAA | P10253 | 5/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11689294 | 0.81 | KMT2A (0.70) | MGLLALDH1A1HPGDSMN1; SMN2KMT2A | |
| SCHEMBL12632654 | 0.81 | F2 (0.52) | MGLLALDH1A1HPGDSMN1; SMN2KMT2A | |
| SCHEMBL1421274 | 0.81 | GAA (0.69) | MGLLALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL181733 | 0.80 | KMT2A (0.64) | MGLLALDH1A1HPGDSMN1; SMN2KMT2A | |
| SCHEMBL3798127 | 0.78 | KMT2A (0.52) | MGLLALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL11025571 | 0.77 | CA12 (0.61) | ALDH1A1KMT2AMEN1GAAPOLB | |
| SCHEMBL7297607 | 0.77 | DHODH (0.51) | ALDH1A1KMT2AMEN1GAAPOLB | |
| SCHEMBL11028524 | 0.75 | CA2 (0.43) | ALDH1A1HPGDSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL3780616 | 0.73 | LMNA (0.67) | MGLLALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL10570978 | 0.70 | L3MBTL1 (0.44) | MGLLALDH1A1SMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7939554-B2 | Of Src homology protein tyrosine phosphatase 1; phenyl isothiazolones or a benzo-1,4-quinone; antineoplastic agents; immunostimulants inducing a cytokine response; side effect reduction | THE CLEVELAND CLINIC FOUNDATION (US) | 2011-05-10 | — | — | US | disclosed |
| US-20080103160-A1 | Protein phosphatase inhibitors | THE CLEVELAND CLINIC FOUNDATION | 2008-05-01 | — | — | US | disclosed |
| US-20080051464-A1 | Protein phosphatase inhibitors | THE CLEVELAND CLINIC FOUNDATION | 2008-02-28 | — | — | US | disclosed |
| WO-2008002641-A2 | PROTEIN PHOSPHATASE INHIBITORS | THE CLEVELAND CLINIC FOUNDATION (US) | 2008-01-03 | — | — | WO | disclosed |
| US-6921760-B2 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER INC. (US) | 2005-07-26 | — | — | US | disclosed |
| US-6627627-B2 | Useful as psychotherapeutic agents | PFIZER INC. | 2003-09-30 | — | — | US | disclosed |
| EP-1339696-A1 | BENZYL(IDENE)-LACTAMS AND THEIR USE AS 5HT1-RECEPTOR LIGANDS | Pfizer Products Inc. (US) | 2003-09-03 | — | — | EP | disclosed |
| EP-0929528-B1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER (US) | 2003-07-23 | — | — | EP | disclosed |
| US-6562813-B2 | Psychological disorders; antiserotonin agents; headache therapy | PFIZER INC. | 2003-05-13 | — | — | US | disclosed |
| US-6472388-B2 | PSYCHOTHERAPEUTIC AGENTS. | PFIZER INC | 2002-10-29 | — | — | US | disclosed |
| US-20020147194-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER INC. | 2002-10-10 | — | — | US | disclosed |
| US-6423708-B1 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER INC | 2002-07-23 | — | — | US | disclosed |
| US-20020091117-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER INC. | 2002-07-11 | — | — | US | disclosed |
| US-20020091118-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER INC. | 2002-07-11 | — | — | US | disclosed |
| US-20020091119-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER INC. | 2002-07-11 | — | — | US | disclosed |
| WO-2002046167-A1 | BENZYL (IDENE)-LACTAMS AND THEIR USE AS 5HT1-RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 2002-06-13 | — | — | WO | disclosed |
| US-20020072519-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER INC. | 2002-06-13 | — | — | US | disclosed |
| US-6403592-B1 | SEROTONIN REUPTAKE INHIBITORS | PFIZER INC | 2002-06-11 | — | — | US | disclosed |
| US-6380186-B1 | PSYCHOTHERAPEUTIC AGENTS | PFIZER INC | 2002-04-30 | — | — | US | disclosed |
| US-20020049214-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER PRODUCTS INC. | 2002-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091118-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | MRPL21, ARAF, ARL1 | MGLL 368/4885ALDH1A1 1607/4885HPGD 1937/4885 |
| US-20020091119-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | MRPL21, ARAF, ARL1 | MGLL 368/4885ALDH1A1 1607/4885HPGD 1937/4885 |
| US-20020147194-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | MRPL21, ARAF, ARL1 | MGLL 368/4885ALDH1A1 1607/4885HPGD 1937/4885 |
| US-20020049214-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | MRPL21, ARAF, ARL1 | MGLL 284/4885ALDH1A1 1434/4885HPGD 2268/4885 |
| US-20080103160-A1 | Protein phosphatase inhibitors | PPM1A, DUSP15, PPM1B | MGLL 3271/4885ALDH1A1 1282/4885HPGD 1845/4885 |
| US-20020072519-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | MRPL21, ARAF, ARL1 | MGLL 368/4885ALDH1A1 1607/4885HPGD 1937/4885 |
| US-20020091117-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | MRPL21, ARAF, ARL1 | MGLL 368/4885ALDH1A1 1607/4885HPGD 1937/4885 |
| US-20080051464-A1 | Protein phosphatase inhibitors | PPM1A, DUSP15, PPM1B | MGLL 3271/4885ALDH1A1 1282/4885HPGD 1845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.